Marcq En Baroeul

This research aims to evaluate the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis. The study is conducted in France and focuses on understanding how this treatment performs outside of controlled clinical trial settings. Participants in this observational study will be newly starting deucravacitinib as prescribed by their treating clinician. There are no additional study treatments or placebo groups, as the study observes the outcomes of the treatment during routine clinical care. During the study, researchers will assess clinical outcomes including the Physician's Global Assessment (PGA) and the Dermatology Life Quality Index (DLQI) at baseline and at months 4, 12, 18 (optional), and 24. They will also monitor how long participants remain on deucravacitinib treatment, up to 24 months. These evaluations help to measure both the effectiveness and impact on quality of life for participants with plaque psoriasis.

This research aims to evaluate the real-life effectiveness, safety, usage, tolerance, and satisfaction of four CE-marked isotonic and hypertonic seawater-based nasal sprays. It focuses on infants, children, adults, and pregnant or breastfeeding women who suffer from acute and chronic sinonasal conditions such as upper respiratory tract infections, COVID-19, bronchiolitis, allergic rhinitis, chronic rhinosinusitis, and post-surgery recovery. The study seeks to answer key questions on how well these nasal sprays work and how safe and satisfactory they are in everyday use. Participants will use one of four nasal sprays designed for different age groups and indications. The sprays are applied by spraying 1 to 3 seconds into each nostril multiple times daily, depending on the product and condition. Treatment for nasal symptoms ranges from 2 to 6 times a day, while hygiene and prevention uses are less frequent. The nasal sprays are used according to their intended purpose and population, including special instructions for babies, children, and adults. During the study, participants or their parents/caregivers will perform nasal washes following healthcare provider advice and complete online questionnaires about their symptoms and experience. Researchers will monitor nasal symptom improvement over 5 days for acute conditions and up to 14 days for chronic conditions. The study includes assessments of nasal symptom intensity, nasal breathing impairment, safety, and user satisfaction. Participants are expected to comply with study requirements for up to 3 months and have daily internet access for questionnaire completion.

This research aims to assess the long-term performance and safety of ATF Implants and Lapé Médical devices used in hip replacement surgeries, including total hip arthroplasty or hemiarthroplasty. It is a prospective, observational, multicenter study designed to collect clinical evidence over a 10-year period. The study focuses on patients receiving these specific hip prostheses to better understand their durability and safety outcomes. The study involves patients undergoing hip replacement surgery with implants manufactured by ATF Implants and Lapé Médical. Surgeons will select the most appropriate prosthesis based on individual patient factors and device instructions at the time of surgery. The evaluation includes monitoring both the hip prostheses and the surgical instruments used for their placement throughout the 10-year follow-up. Participants will be followed before and after surgery with regular evaluations by surgeon-investigators using established orthopedic criteria. Data on complications, adverse effects, and prosthesis performance will be recorded. The main outcome measured is the long-term survival rate of the implants over 10 years. Additional assessments will include safety, performance, and user feedback on the devices and instruments during the study period.